CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00431-07v1
15/3/460    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Swenson, D. L.
Right arrow Articles by Pratt, W. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swenson, D. L.
Right arrow Articles by Pratt, W. D.
Clinical and Vaccine Immunology, March 2008, p. 460-467, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00431-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections{triangledown}

Dana L. Swenson,1 Danher Wang,2 Min Luo,2 Kelly L. Warfield,1 Jan Woraratanadharm,2 David H. Holman,2 John Y. Dong,2,3 and William D. Pratt1*

U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, Frederick, Maryland 21702-5011,1 Division of Biodefense Vaccines, GenPhar, Inc., 600 Seacoast Pkwy, Mount Pleasant, South Carolina 29464-8247,2 Department of Microbiology and Immunology, Medical University of South Carolina, 173 Ashley Ave., BSB 201, Charleston, South Carolina 294033

Received 1 November 2007/ Returned for modification 23 December 2007/ Accepted 7 January 2008

Filoviruses (Ebola and Marburg viruses) are among the deadliest viruses known to mankind, with mortality rates nearing 90%. These pathogens are highly infectious through contact with infected body fluids and can be easily aerosolized. Additionally, there are currently no licensed vaccines available to prevent filovirus outbreaks. Their high mortality rates and infectious capabilities when aerosolized and the lack of licensed vaccines available to prevent such infectious make Ebola and Marburg viruses serious bioterrorism threats, placing them both on the category A list of bioterrorism agents. Here we describe a panfilovirus vaccine based on a complex adenovirus (CAdVax) technology that expresses multiple antigens from five different filoviruses de novo. Vaccination of nonhuman primates demonstrated 100% protection against infection by two species of Ebola virus and three Marburg virus subtypes, each administered at 1,000 times the lethal dose. This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack.

* Corresponding author. Mailing address: USAMRIID, 1425 Porter Street, Ft. Detrick, MD 21702. Phone and fax: (301) 619-2405. E-mail: william.pratt{at}amedd.army.mil

{triangledown} Published ahead of print on 23 January 2008.

Clinical and Vaccine Immunology, March 2008, p. 460-467, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00431-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.